Results 241 to 250 of about 246,153 (308)

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. [PDF]

J Infect Dis
Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, Grunenberg N, Laher Omar F, Seaton KE, Polakowski L, Woodward Davis AS, Maganga L, Baden LR, Mayer K, Kalams S, Keefer M, Edupuganti S, Rodriguez B, Frank I, Scott H, Stranix-Chibanda L, Gurunathan S, Koutsoukos M, Van Der Meeren O, DiazGranados CA, Paez C, Andersen-Nissen E, Kublin J, Corey L, Ferrari G, Tomaras G, McElrath MJ.   +31 more
europepmc   +1 more source

Reference Intervals for Lymphocyte Subpopulations in Healthy Chinese Han Adults: A Single‐Center Study

Journal of Clinical Laboratory Analysis, Volume 40, Issue 3, February 2026.
Correlation matrix analysis of lymphocyte parameters. The correlation matrix showed the positive (red) or negative (blue) correlation of two parameters; the color intensity reflected the correlation coefficient. Conducting lymphocyte testing in health management can help monitor immune status, evaluate health risks, analyze pathogenesis of diseases ...
An‐Na Jiang, Lin‐Zi Miao, Yan Gong, Ran You, Yao Lu, Chen‐Xue Qu   +5 more
wiley   +1 more source

HIV gp120 vaccine (Chiron)

Drugs in R & D, 1999
openaire   +2 more sources

Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption

Journal of the International AIDS Society, Volume 29, Issue 2, February 2026.
Abstract Introduction The development of approaches and interventions to achieve HIV remission continues to accelerate. Children living with HIV who started antiretroviral therapy (ART) at a young age and sustain viral suppression are an ideal clinical trial population. Trials may require analytic treatment interruptions (ATIs).
Holly L. Peay, Kennedy Otwombe, Shaun Barnabas, Ana Barrios‐Tascon, Maria Grazia Lain, Tacilta Nhampossa, Diana Rutebarika, Thidarat Jupimai, Moherndran Archary, Almoustapha‐Issiaka Maiga, Avy Violari, Moira J. Spyer, Kavidha Reddy, Paolo Palma, Savita Pahwa, Mathias Lichterfeld, Mark Cotton, Louise Kuhn   +17 more
wiley   +1 more source

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06). [PDF]

EClinicalMedicine
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, Durand M, Rieux V, Diallo A, Lacabaratz C, Cardinaud S, Zurawski S, Zurawski G, Tomaras GD, Ding S, Centlivre M, Thiebaut R, Pantaleo G, Lelièvre JD, Richert L, ANRS VRI06 Study Group.   +20 more
europepmc   +1 more source

Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications

MedComm, Volume 7, Issue 2, February 2026.
The microbiome is related to the efficacy of immunotherapy and can be utilized to predict the efficacy and adverse reactions of immunotherapy. Microbiome‐targeted intervention strategies can improve the efficacy of ICI, but necessitating more comprehensive exploration.
Anqi Lin, Minying Xiong, Aimin Jiang, Li Chen, Lihaoyun Huang, Kailai Li, Hank Z. H. Wong, Jian Zhang, Zaoqu Liu, Quan Cheng, Bufu Tang, Pengpeng Zhang, Peng Luo   +12 more
wiley   +1 more source

Should HIV Vaccines Be Made Available at No or Subsidized Cost? A Qualitative Inquiry of HIV Vaccine Trial Stakeholders in Tanzania. [PDF]

AJOB Empir Bioeth
Pancras G, Ezekiel M, Mbugi E, Merz JF.
europepmc   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source